Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.
Abstract
In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy (SCAP) method and conducted a survey regarding treatment satisfaction. The switch from polypharmacy to monotherapy was achieved in all patients. There was no deterioration in psychiatric symptoms, and adverse reactions were reduced. Three of the subjects were satisfied with the decrease in the number of antipsychotic agents and dose-reduction. These results suggest that the SCAP method is a safe and useful method that can be applied in a clinical setting.
참고문헌 (13)
- Essock SM, "Identifying clinically questionable psychotropic prescribing practices for medicaid recipients in New York state", Psychiatr Serv, 60, pp.1595~1602 (2009)
- Correll CU, "Schizophrene Stoerungen-State of the Art III", pp.95~112 (2004), Verlag Integrative Psychiatrie
- Essock SM, "Effectiveness of switching from antipsychotic polypharmacy to monotherapy", Am J Psychiatry, 168, pp.702~708 (2011)
- Suzuki T, "Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia", Int J Neuropsychopharmacol, 7, pp.133~142 (2004)
- Yoshio T, "Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia : comparison between 2007 and 2009", Hum Psychopharmacol, 27, pp.70~75 (2012)
- Okumura Y, "Antipsychotics prescribing patterns of patients with schizophrenia in Japan: using the national database of health insurance claim information and specified medical checkups", Jpn J Clin Psychopharmacol, 16, pp.1201~1215 (2013)
- Fleischhacker WW, "Critical review of antipsychotic polypharmacy in the treatment of schizophrenia", Int J Neuropsychopharmacol, 17, pp.1083~1093 (2014)
- Sukegawa T, "Study protocol : safety correction of high dose antipsychotic polypharmacy in Japan", BMC Psychiatry, 14, pp.103~ (2014)
- Yamanouchi Y, "Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method", Int J Neuropsychopharmacol, 18, pp.pyu016~ (2014)
- Shikata Y, "Effect of inpatient pharmaceutical service for the doses on psychiatric drug therapy", J Jpn Soc Hosp Pharm, 50, pp.579~584 (2014)
- Galderisi S, "Social skills and neurocognitive individualized training in schizophrenia : comparison with structured leisure activities", Eur Arch Psychiatry Clin Neurosci, 260, pp.305~315 (2010)
- Palumbo D, "SoCIAL-training cognition in schizophrenia : a pilot study", Neuropsychiatr Dis Treat, 13, pp.1947~1956 (2017)
- Kao CC, "A comparison of the quality of life of patients with schizophrenia in daycare and homecare settings", J Nurs Res, 22, pp.126~135 (2014)